Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial.

Masanori KatoHidetoshi ItoAkane YamakawaTatsuo KagimuraMasafumi FukagawaMasahiro YamamotoYoshinori SaitoTadao Akizawa Hiroaki Ogata

Published in: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2024)

Aspirin use was not significantly associated with a lower risk of CVEs in participants undergoing hemodialysis patients at risk of vascular calcification.

Keyphrases

cardiovascular events
chronic kidney disease
end stage renal disease
patients undergoing
coronary artery disease
peritoneal dialysis
cardiovascular disease
study protocol
phase iii
clinical trial
low dose
phase ii
randomized controlled trial
type diabetes
percutaneous coronary intervention
atrial fibrillation